Osimertinib is a third-generation EGFR-TKI that was developed to address this issue [12], and the AURA3 study revealed that it provided significantly longer PFS compared to platinum-based chemotherapy among patients with T790M-mutated lung cancer [13]. The gene discussed is EGFR; the disease is lung cancer.